Blogs

The data the biotech industry generates, consumes and shares is very often not only extremely sensitive (expensive to create, the product of some of the finest minds and technically focused facilities on the earth, in some cases connectable to the very fabric of humanity), it’s impossible to de-sensitise once lost to an attacker. 

The relaunched APPG for Life Sciences holds its inaugural parliamentary reception, bringing together MPs, Peers, and sector leaders to showcase UK life sciences innovation.

 This week’s blog explores the dynamic intersection of life sciences, policy, and innovation. From groundbreaking collaborations in the UK to navigating the shifting IP landscape in North America, I reflect on how our sector continues to lead and adapt in a rapidly changing world.

In this article, Giuseppe Amoroso, R&D Tax Advisor for biotech companies, explores the critical role of R&D tax compliance in the biotechnology sector.

Glox Therapeutics' expanded team to support development and commercialisation of precision antibiotics to help overcome antimicrobial resistance.

Apprenticeships offer a cost-effective way to develop talent, bridge skills gaps, and drive business growth—find out how they can deliver real ROI for your organisation.

The UK’s biotech sector continues to break new ground, from sustainable medicine manufacturing to AI-driven healthcare advancements. This week, I analyse key developments shaping the industry, including the launch of the Sustainable Medicine Manufacturing Innovation Programme, the BIA’s role in the government’s Spending Review, and the UK’s leadership in cultivated meat.

Celebrating success for UK life sciences with a landmark week.

As Donald Trump returns to the White House, the biotech industry is assessing what his presidency means for investment and innovation. With the UK’s life sciences sector gaining strength, could this be the moment to turn uncertainty into opportunity?

This week our new BIA UK biotech financing report shows £3.5 billion invested in 2024, I detail the launch of the STVC Fellowship, look at the impact of the proposed US withdrawal from WHO, and news from Davos on groundbreaking AI-driven drug trials by Isomorphic Labs.

In this article, Dr. Fawzi Abou-Chahine, Grants Director at FI Group UK, delves into the evolving landscape of grant funding in the biotechnology sector.

TechBio's 2024 breakthroughs proved it’s not just innovating—it’s transforming healthcare, with the UK leading the charge into a future where biology, tech, and data redefine possibilities.

The BIA is driving progress across life sciences, from shaping policy in engineering biology and advocating for balanced perspectives in the Covid Inquiry to exhibiting UK innovation at JP Morgan Healthcare Week. 

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at the BIA, shares our perspective on the recent EngBio public trust survey findings conducted by the DSIT.

UK dealmakers are at the heart of JPM, the Government rolls out AI plan and new MHRA Chair sets priorities.

In this blog Izzy Webb, Deputy Director for technology, strategy and security in the Department for Science, Innovation and Technology (DSIT), discusses the UK Government's survey on engineering biology, outlining its limited public awareness but sharing optimism about its potential to address societal challenges.

Third-Party Cyber Security (TPCS) is a cyber security firm specialising in helping growth companies assure investors, partners, and customers that cyber security is well managed within the business.

In this guest blog, Christine Hockley, Managing Director at British Patient Capital, outlines the substantial long-term investment needed to scale innovations.

The global life science investment and media community are heading to the JPM Healthcare Conference next week and we’ll be keeping an eye on announcements and grants that impact our industry.

New legislation was laid in Parliament last Thursday to modernise the regulation of clinical trials in the UK.